CD19 CAR-T cell therapy (National University of Malaysia)

靶向CD19的嵌合抗原受体T细胞 (National University of Malaysia)

Report date: 2025/07/29 20:00:11

Base Information

Drug NameCD19 CAR-T cell therapy (National University of Malaysia)
Drug Alias NameAutologous CD19 Chimeric Antigen Receptor (CAR)-T Cells therapy (National University of Malaysia)Autologous CD19 CAR-T Cells therapy (National University of Malaysia)Autologous CD19 CAR-T cells therapy (National University of Malaysia)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, SystemicLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMalaysia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational University Of MalaysiaPlutonet Sdn Bhd
China Registration ClassN/A

Develop Information

Active CompaniesPlutonet Sdn BhdNational University Of Malaysia
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A